All In MedTech

Device Trial Radar · NCT04601155

Transition of Renal Patients Using AlloSure Into Community Kidney Care

Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

248

Actual

Start

Nov 19, 2020

Primary completion

Mar 24, 2023

Study completion Oct 6, 2023

Sponsor

Lead sponsor
CareDxNot on our public-company list
Sponsor type
Industry
First posted
Oct 23, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients undergoing kidney transplantation alone (either de-novo or re-transplant) at a participating hospital are routinely surveyed with interval blood tests as part of standard post-operative care through outpatient consultation. These tests include serum creatinine, blood sugar as well as DSA testing at various intervals. The ability to screen patients to better identify those who may be at risk of developing an adverse event using AlloSure cfDNA is likely to be advantageous, with the potential to improve graft survival and outcomes for transplant patients. The addition of AlloSure to the interventional group will be the focus of this study. Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years.Participants will attend outpatient visits/follow-up visits as part of their standard care, these will include appointments where they will have blood tests taken as part of post-transplant surveillance. For AlloSure cfDNA and DSA, blood will be taken quarterly.

Conditions

  • Kidney Transplant Rejection

Interventions

  • AlloSureDevice

    AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Superior allograft survivalTime frame: 5 years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Amicis Research Center

    Fairfield, California

  • The Medical Research Group - Fresno

    Fresno, California

  • Amicis Research Center

    Granada Hills, California

15 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.